Professional
Added to YB: 2024-05-17
Pitch date: 2024-05-10
GH [bullish]
Guardant Health, Inc.
+640%
current return
Author Info
No bio for this author
Company Info
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Market Cap
$22.3B
Pitch Price
$22.70
Price Target
47.00 (-72%)
Dividend
N/A
EV/EBITDA
-61.19
P/E
-49.33
EV/Sales
21.18
Sector
Health Care Providers and Services
Category
growth
Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next
GH: Q1 strong start - rev $169M (+31% YoY), 61% margin. Expect FY rev growth 17.5%+ & FCF -$275M. 5/23 FDA review of Shield CRC test key. Potential large market in MRD & CRC screening, but still early & reimbursement unclear. bears: competition, uncertainty on coverage/usage. No moat yet. FVE $47 on conservative assumptions. Very high uncertainty rating - cash flow positive not until ~2028, but CRC screening & MRD are promising long-term.
Read full article (9 min)